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Lung cancer continues to be one of the most prevalent malignancies worldwide and is the leading cause of death
in both men and women. Presently, local control rates are quite poor. Improvements in imaging and radiation
treatment delivery systems however have provided radiation oncologists with new tools to better target these
tumors. Stereotactic body radiation therapy (SBRT) is one such technique that has shown efficacy as upfront
treatment for lung cancer. In addition, more recent studies have demonstrated some effectiveness in recurrent
tumors in prior irradiated fields as well. This review summarizes seven recent studies of re-irradiation with SBRT in
patients with thoracic recurrences treated previously with conventionally fractionated radiation therapy. Combined,
140 patients were included. The median initial thoracic radiation doses ranged from 50-87.5 Gy and median
re-irradiation dose ranged from 40-80 Gy. Local control rates varied from 65-92%. Re-irradiation was well tolerated
with few grade 4 and 5 complications (observed in one study). Currently, based on these published reports,
re-irradiation with SBRT appears feasible for in-field thoracic recurrences, though caution must be taken in all
cases of retreatment.
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There are approximately 228,000 new cases of lung cancer
diagnosed in the United States each year and approxi-
mately 70% of patients with lung cancer receive external
beam radiation treatment (EBRT) as one component of
their treatment [1]. Despite advancements in imaging, sta-
ging and treatment with surgery, radiation, and chemo-
therapy, rates of locoregional recurrence in lung cancer
continue to be high. Studies have cited thoracic recur-
rences or new metachronous primary lung tumor in the
range of 4-10% [2,3]. Other studies using bronchoscopy to
evaluate response after treatment found significantly worse
outcomes, with less than 20% of later stage non-small cell
lung cancer patients experiencing a complete resolution of
their disease 3 months after standard course fractionation
(2 Gy) [4]. As systemic treatment continues to improve,
local disease control has become increasingly important.
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unless otherwise stated.within prior radiation fields, pose a significant challenge
for radiation oncologists. Stereotactic body radiation ther-
apy (SBRT) has become a more commonly used modality
to treat both primary and recurrent disease and has signifi-
cantly impacted the local control rates in lung cancer.
SBRT was derived from intracranial stereotactic radio-
surgery (SRS), which was first presented in 1951 [5]. In
2001, SRS was approved by the US Food and Drug
Administration to treat areas throughout the body and the
first SBRT delivery system was established. Immobilization
devices and improved real-time imaging have allowed cli-
nicians to administer high ablative doses to accurately tar-
get the tumor. The effectiveness of SBRT arises from the
cumulative biologically effective dose (BED) it can achieve
while maintaining a sharp dose gradient fall off outside the
target, preventing dose to critical structures. Reaching a
high BED has been shown to improve overall survival and
local tumor control rates in many tumors [6]. Martel and
colleagues published a dose-escalation study in patients
with inoperable non-small cell lung cancer (NSCLC),
achieving doses as high as 103 Gy in 2 Gy fractions [7].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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between dose and recurrence free survival, suggesting
doses up to 84 Gy are needed to achieve greater
progression-free survival. A review of 13 randomized con-
trolled trials for palliative thoracic radiotherapy found im-
provements in symptom control and survival at one year
with 35 Gy10 BED schedules [8]. Onishi et al [9] de-
monstrated a local control rate of 92% for those receiv-
ing SBRT with a BED > 100 Gy compared to 74% with a
BED < 100 Gy. In addition, higher dose per fraction treat-
ments given over a shortened timed frame in comparison
to conventional fractionation may reduce the rate of re-
population in tumor cells [10]. More comformal delivery
also leads to smaller treatment field margins which in turn
relates to lower toxicity and is especially important in the
setting of re-irradiation.
For recurrent disease in the thorax, especially within
the previous radiation field, salvage surgery is typically
avoided. Therefore most institutions favor chemotherapy.
Unfortunately the current response rates for second and
third line chemotherapy remain quite poor, leaving fairly
few options for these patients [11]. The use of re-
irradiation has been studied in several regions of the body,
most notably in the head and neck. Overall, retreatment
in these studies was well tolerated and local control rates
were acceptable [12,13]. For example, a phase I SBRT,
dose-escalation, re-irradiation study for patients with re-
lapsed head and neck squamous cell cancer demonstrated
tolerable side effects in those treated up to 44 Gy in 5 frac-
tions given over 2 weeks [12]. Treatment response was
observed in up to 76% of patients in the study, with a me-
dian disease free progression of 4 months. There were no
grade 3 or 4 toxicities. Extrapolating from this data and
the manuscripts reviewed here, SBRT is suggested to be
an advantageous approach for recurrent NSCLC after
prior conventional radiation.
SBRT in recurrent thoracic tumors
SBRT for lung tumors
SBRT for primary treatment of early stage lung cancer
has been well established with multiple prospective trials
[14]. Local control rates for early stage lung cancer using
SBRT are greater than 90% [15-17]. The initial phase I
study assessing dose escalation using SBRT for inoper-
able lung cancer used starting doses of 24 Gy in 3 frac-
tions [15]. The maximum-tolerated dose was never
achieved for T1 tumors while T2 tumors reached 60-66
Gy in 3 fractions with tolerable toxicities. Dose limiting
toxicities for larger tumors (5-7 cm) included bronchial
injury, pneumonia, and pericardial effusion. The phase II
study used a total dose of 60-66 Gy in 3 fractions [18].
Three-year cancer-specific survival in this study was
81.7%. Grade 3 to 5 toxicity occurred more commonly
in central tumors (27.3% versus 10.4%) [19]. While thereare a number of studies describing upfront SBRT for
NSCLC, there is little data describing the use of SBRT in
the re-irradiation setting for NSCLC.
The following section will present fairly recent data on
SBRT for lung cancer patients previously treated with con-
ventional fractionation. There are a number of limitations
addressed in these studies. Overall patient numbers are
few and follow up is short. Patient selection and population
heterogeneity in those retreated provides some difficulty
when comparing results of these studies conducted at the
various institutions discussed. Patients included in the
study had re-irradiation at any location in the thorax, not
necessarily overlapping the initial field of treatment and
often times in a separate ipsilateral or contralateral lobe.
Toxicity rates and outcomes would likely vary substantially
depending on the proportion of patients retreated with
true overlapping fields. In addition, the radiation delivery
technique and dosing used is quite variable across these
studies. Lastly, there is selection bias in those receiving re-
irradiation as they are usually better equipped to tolerate
re-irradiation and usually have limited systemic progres-
sion compared to those who are not candidates [20].
Summary of re-irradiation studies
SBRT for thoracic re-irradiation has only recently been
published (Table 1). These studies are small in nature. Sev-
eral as will be mentioned include both re-irradiation in
and outside the original treatment field. The first is a
retrospective study conducted at MD Anderson analyzing
outcomes in retreated lung cancer patients with SBRT
[21]. The study included all thoracic re-irradiation cases
(both in and outside the original treatment field). In field
re-irradiation including any overlap within the prior high
dose region defined as >30 Gy. The most common re-
irradiation regimen was 50 Gy in 4 fractions (72% of pa-
tients). Local control rates were 92%. Three out of the 22
intrathoracic failures occurred within the SBRT field and
of those, 2 had received suboptimal dosing and coverage.
Patients treated for out-of-field relapses had improved
progression free survival time as compared to patients
with in-field relapses. Median overall survival at 2 years
was 59%. Toxicities noted in the study included grade 3
pneumonitis (28%), grade 3 esophagitis (8%), grade 3 skin
changes (6%), and grade 3 cough (3%). Grade 3 pneumon-
itis correlated with retreatment of out-of-field relapse (p =
0.03). No grade 3 pneumonitis was observed with in-field
retreatment. There were no grade 4 or 5 toxicities reported.
Stanford University recently published their SBRT re-
irradiation experience as well [22]. The study included 15
patients treated with SBRT to in-field recurrences alone.
This included patients initially treated with either conven-
tional fractionation (n = 11) or SBRT (n = 4). They com-
pared this cohort to those patients at their institution who
received primary SBRT as their initial treatment. Median
Table 1 SBRT Thoracic Re-irradiation Studies
Study Coon et al [24] Kelly et al [21] Trakul et al [22] Reyngold et al [23] Ester et al [25] Trovo et al [27] Seung et al [26]
Number of
Patients
12 36 15 39 13 17 8
First Radiation
Dose
n/a 61.5 Gy (range 30-79.2) Median BED 87.5 Gy
(range 60-112.5)




n/a 22.0 mo (range 0-92) 16 mo (range 5-80) 37.0 mo (range 1-180) 19.7 mo (range 4.7-84.7) 18 mo (range 1-60) 367.0 mo (range 8-57)
Re-irradiation Dose 60 Gy 50 Gy (72%), 40 Gy
(17%), Other (11%)
median BED 80 Gy
(60-112.5)
median BED 70.4 Gy
(range 42.6-180)
9-10 Gy x5 30 Gy (5-6 fx) 12 Gy x4, 10 Gy x5, 8
Gy x5, 20 Gy x3
Target Size (range) median GTV 14.3
cc
tumor (median) 1.7 cm
(range 0.6-3.8)
14.2 ml (range 2-57.7) median GTV 19.0 cc (0.7-227) n/a n/a n/a
Follow up
(median)
12 mo 15 mo (range 4-45) 15 mo (range 4-65) 12.6 mo (range 1.3-47.5) 11.4 mo (0.9-38.3) 18 mo (range 4-57) 18 mo (range 11-20)
Local Control 92% 92% 65.5% 77% (1-year LPFS) 92% 86% 86%
Overall Survival 67% (1-year) 59% (2-years) 80% (1-year) 22.0 months (MS) n/a 59% (1-year) n/a
Toxicity no G3 G3 pneumonitis (28%),
G3 esophagitis (8%), G3
skin (6%), G3 cough
(3%), No G4/5 toxicities
chest wall pain (6.7%),
esophagitis (0.9%), no G2
or higher pneumonitis,
no G4 or higher toxicities
G2 pulmonary (18%), G3
pulmonary (5%), G2/3 chest wall
pain (18%), G2/3 fatigue (15%),










G1 cough (13%), G1
pain (13%), G2
dyspnea (100%)
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When comparing outcomes of SBRT for recurrent in-field
tumors compared to up front SBRT for primary/initial
treatment, 12-month local control rates were 65.5% com-
pared to 92.1% respectively. Kaplan-Meier estimates dem-
onstrated those with a shorter interval between treatments
(≤16 months) had lower rates of local control (46.5% vs.
87.5%, p = 0.042). Re-irradiation was well tolerated in all
cases, including grade 2 or higher pneumonitis (11.6%),
chest wall pain (6.7%) and esophagitis (0.9%). One individ-
ual developed ipsilateral vocal cord paralysis which may
have been treatment related as the treated site was located
adjacent to the aortic notch.
Reyngold et al [23] also recently published the results
of 39 patients with prior intra-thoracic conventional ra-
diation who underwent SBRT for either a new primary,
recurrent (in or out-of-field) or metastatic lung tumor at
Memorial Sloan Kettering Cancer Center. Of the 39 pa-
tients retreated, 22 (56%) individuals had overlap with
prior radiation fields. Multiple SBRT regimens were in-
cluded: 60 Gy, 50 Gy and 48 Gy in 3 fractions, 40-45 Gy
in 5 fractions, 20-22 Gy in 1 fraction, 32-35 Gy in 4-5
fractions, and 27.5-30 Gy in 5 fractions. The local pro-
gression free survival (LPFS) rates at 1- and 2-years for
the entire cohort were 77% and 64% respectively. Toxic-
ities included grade 2 or 3 pulmonary (dyspnea, hypoxia,
cough, pneumonitis) (23%), chest wall pain (18%), fa-
tigue (15%), and skin/soft tissue breakdown (5%). There
were no reported grade 5 toxicities. SBRT doses with a
BED10 ≥ 100 Gy vs. < 100 Gy and overlap with the prior
radiation field did not correlate with pulmonary toxicity.
Factors associated with improvement in LPFS were no
overlap with the prior radiation field (p = 0.04), BED10 ≥
100 Gy (p = 0.04), time interval greater than 36 months
between treatments (p = 0.05), PTV < 75 cm3 (p = 0.03),
and KPS ≥ 80 (p = 0.03).
Coon et al [24] published their data from the University
of Pittsburgh Cancer Center. The study included 12 pa-
tients with residual/recurrent lung cancer after previous
treatment. Patients were treated to a dose of 60 Gy in 3
fractions, prescribed to the 80% isodose line. After a me-
dian follow up of 12 months, local control rates were 92%
in patients with recurrent lung cancer. Treatment was well
tolerated with one grade 2 radiation pneumonitis and an-
other patient with exacerbation of chronic obstructive pul-
monary disease, which reportedly was treatment and/or
tumor related with no grade assigned. The University of
Minnesota recently presented their re-irradiation experi-
ence as well [25]. Ten patients included had initially re-
ceived conventional fractionation followed by re-irradiation
with SBRT. Local control rates were 92% and pulmonary
toxicities included one grade 2, one grade 3, and no grade
4 or 5 complications. Seung et al [26] looked at their insti-
tutional experience as well, including 8 patients retreatedwith SBRTafter definitive radiation therapy and found local
control rates of 86%. Pulmonary toxicities include one
grade 1 cough, one grade 1 pain, eight grade 2 dyspnea
with no grade 3 or greater side effects.
Most recently, a group in Italy published their retro-
spective data on 17 patients with in-field centrally lo-
cated NSCLC who received re-irradiation with SBRT
[27]. Centrally located tumors were defined as being lo-
cated 2 cm in all directions around the proximal bron-
chial tree. All patients included were treated with prior
conventional radiation therapy (50-60 Gy in 20-30 frac-
tions) and only in-field recurrences were included. The
SBRT dose given was 30 Gy in 5 or 6 treatments with
cumulative doses ranging from 87-100 Gy. With a follow
up of 18 months, local control rates were 86% with 1
and 2 year overall survival rates of 59% and 29% respect-
ively. The significance of this study was the reported
grade 5 toxicities, which included one patient who died
of hemoptysis 2 months after finishing treatment and
another patient who died from pneumonitis 4 months
after treatment. Patients in the study who developed
grade 3-5 pneumonitis had a higher heart maximum
dose (Dmax), a minimum dose to at least 5% of the
heart volume (D5) mean of 10 Gy, and a minimum dose
to at least 10% of the heart volume (D10) mean of 3 Gy
(p < 0.05).
Toxicities
As there is relatively little data published on re-
irradiation using SBRT, the side effect profile is still not
fully characterized. Acute toxicities from SBRT may be
as common as 40% and include fatigue, skin erythema,
hematologic suppression and cough; late toxicities are
less common and included pneumonitis, scarring, wors-
ening pulmonary function, chest wall pain, rib fractures,
esophageal injury and brachial plexopathy [28]. Pneu-
monitis appears to be the most common side effect
from retreatment, up to 40% in some cases [21]. Liu et
al [29] analyzed rates of pneumonitis in those receiving
conventional fractionation followed by re-irradiation
with SBRT for recurrent disease. Rates of severe pneu-
monitis were common (20.8%), with predictive factors
including performance status, forced expiratory volume
in one second (FEV1), initial planned tumor volume
(PTV) including bilateral mediastinum, and those re-
ceiving doses ≥ 20 Gy (V20) to 30% or more of the com-
posite volume. In general, long term side effects in these
patients are more difficult to assess given the shortened
median survival in patients with recurrent lung tumors.
Evans et al [30] found grade 5 aortic toxicities as high as
6% in patients with composite doses ≥ 120 Gy to the
aorta, making note that both severe and fatal toxicities
can and do exist. As described earlier, Trovo et al [27]
unfortunately experienced two treatment-related deaths
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cated recurrences. With fairly high rates of toxicities
seen in multiple thoracic re-irradiation studies as de-
scribed above, physicians must remain vigilant to nor-
mal tissue structure doses, especially in cases of re-
irradiation near critical structures.
Discussion
For many patients, especially in the recurrent setting, sur-
gery may not be a feasible option. Other local therapy ap-
proaches such as radiofrequency ablation (RFA) have also
been studied for NSCLC but local control rates overall are
lower when compared to SBRT [31]. Therefore, when ad-
ministered safely, as demonstrated in the studies discussed
here, SBRT is a viable option for in-field or out-of-field
lung recurrences. Evidence shows high rates of local con-
trol for early-stage NSCLC but there is limited data on
re-irradiation using SBRT. As discussed earlier, present
studies include a heterogeneous population of patients ini-
tially treated with conventional fractionation followed be
both in-field or out-of-field recurrences treated with
SBRT. Other than Trovo et al [27] which included cen-
trally located recurrences, other re-irradiation studies did
not define the location of the recurrences or comment on
correlation between toxicity and central versus peripheral
re-irradiation. Longer follow up is needed to further evalu-
ate late toxicity which is often a concern with high dose
fractionation.
However, based on the data reviewed here, use of SBRT
for lung re-irradiation, when accounting for normal-tissue
tolerance and location in relation to critical structures,
may be a reasonable salvage option for patients. With im-
proved imaging and radiation techniques, treatment mo-
dalities such as SBRT will continue to grow and be more
commonly utilized throughout the country. Much of this
stems from better targeting with the use of state of the art
image guidance. The introduction of positron emission
tomography (PET) and computerized tomography (CT)
for example has come to play large role in diagnosing, sta-
ging, and providing radiation oncologists with the ability
to further optimize treatment plans, treating smaller vol-
umes with more precise targeting [32-35]. Results from
the ACRIN 6668/RTOG 0235 trial recently published
found post-treatment tumor standardized uptake value
(SUV) to be predictive of outcomes and survival [36]. In
addition, PET scans have allowed for earlier detection of
small, solitary tumors and will continue to play a major
part in identifying early recurrences that may be amenable
to re-irradiation with SBRT [37]. Incorporation of PET for
planning purposes also provides better delineation of the
tumor itself, thus reducing volume and allowing radiation
planners to meet normal-tissue toxicity parameters, es-
pecially in the setting of re-irradiation. For example, PET
can help delineate primary tumors from atelectasis, thusdecreasing final target volumes [38]. Use of PET therefore
could play a role in not only identifying early stage lung
tumors, but also assisting in better target delineation dur-
ing treatment planning. The additional challenge of treat-
ment planning is accounting for tumor motion. There are
several techniques to evaluate tumor motion and assist in
treatment planning, including four-dimensional (4D) CT,
respiratory gating and active breathing control [39-41].
Three-dimensional (3D) assessment of a tumor can be ob-
tained by repeating CT scans acquired asynchronously
based on breathing patterns or CT scans can be repeated
at different states of a breathing cycle to define tumor mo-
tion [10,42]. These techniques help to provide more accur-
ate dose delivery, allowing radiation oncologists to deliver
higher doses with greater conformality and accuracy while
minimizing toxicity [43,44].
Despite improvements in radiation delivery techniques
and biologic advances in chemotherapy, locoregional con-
trol continues to remain a challenge in thoracic tumors,
with failure rates as high as 85% [20,45]. Furthermore,
retreatment of locoregional recurrences can be quite dif-
ficult as therapeutic options are still relatively limited.
Options other than SBRT include conventional or hypo-
fractionated re-irradiation. A recent review included ele-
ven studies reporting outcomes for thoracic re-irradiation
of locally recurrent non-small cell lung cancers (NSCLC)
with conventional or hypofractionated doses [46]. The
studies included in this review rarely used intensity modu-
lated radiotherapy (IMRT) and none included retreatment
with SBRT. The goals of re-irradiation for the majority of
these patients were palliative. Symptom control ranged
broadly from 33% - 100%, with significant improvements
observed in rates of hemoptysis, cough, chest pain and
dyspnea. Median survival times following re-irradiation
ranged from 5 to 14 months while one and two-year sur-
vival rates ranged from 8.7 to 59% respectively. The review
also demonstrated a trend for longer survival times with
higher doses of radiation and found that overall high grade
toxicity was relatively low (3-5%). Toxicities were mostly
grade 1-3, including pneumonitis, rib fractures, skin
toxicity and esophagitis. One treatment-related death
secondary to pneumonitis versus tumor progression
was reported.
Considering re-irradiation with more conventional frac-
tionation over five to six weeks with chemotherapy may
be an option but can be difficult for some patients to toler-
ate as many lung cancer patients also present with a host
of co-morbid illnesses, contributing to their poor perform-
ance status. For elderly patients with poor prognostic fac-
tors including weight loss, Karnofsky performance status
(KPS) scores < 70 and additional health comorbidities,
chemotherapy and more conventional dosing with re-
irradiation given over 4-6 weeks may be difficult to toler-
ate [47]. Several studies have demonstrated the significant
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elderly patients with multiple co-morbidities treated for
lung cancer [48,49]. This population in particular, may
benefit substantially from SBRT, as it can be delivered in a
much shorter treatment course making it more conveni-
ent and tolerable for the patient. Lastly, stereotactic radio-
therapy provides a shortened treatment interval, which
can be effective in local tumor control while minimizing
dose fall off to nearby critical structures. Radiation oncolo-
gists however must continue to remain cognizant as toxic-
ities can be high and fatal as was demonstrated in the
recent Italian study described earlier [27].
There are some limitations in the literature reviewed in
this manuscript. All studies include a short median follow
up, ranging from 11-18 months. This is not only pertinent
when analyzing local control rates but also late toxicities
including lung fibrosis which more commonly occurs 1-2
years after the completion of radiation [50]. Radiation
treatment changes on lung parenchyma often are not
visible until 2-3 years following treatment [51,52]. In
addition, SBRT is more feasible for smaller volume recur-
rences given normal tissue constraints, especially in the
setting of re-irradiation. As described earlier, the described
literature has small patient numbers and includes a het-
erogeneous population with some patients included with
re-irradiation within the previous field or outside it mak-
ing interpretation of some of these studies very difficult.
Description of the initial treatment is also lacking so con-
cluding dose per fraction (conventional vs. hypofractiona-
tion) is not clearly defined. Lastly, several important
factors are not described in the manuscripts presented, in-
cluding the number of central tumors retreated, inclusion
of both BED and physical dose in the papers, and correl-
ation of severe toxicity and cumulative re-irradiation dose.
Future studies will need to analyze re-irradiation dose tol-
erances of centrally located recurrences as toxicity rates
are significantly higher for these patients as demonstrated
by Trovo et al [27].
While there is substantial data and guidelines available
for normal tissue tolerance in upfront radiation treat-
ment, there are few guidelines available for radiation on-
cologists to follow for re-irradiation using SBRT. As
discussed earlier, SBRT for upfront treatment of early
stage NSCLC have high local control rates [19]. The cur-
rently limited amount of retrospective data available and
reviewed in this manuscript for re-irradiation using
SBRT also demonstrates fairly high rates of local control
and tolerable toxicity outcomes with only a few cases of
grade 4 side effects and grade 5 (observed in one study).
Overall, re-irradiation for recurrent or persistent lung
cancers using SBRT is feasible and should be offered to
patients, taking into account performance status, individ-
ual comorbidities and the experience of the clinician in
delivering treatment using these sophisticated techniques.Other local treatment options such as surgery, RFA, and
systemic agents should be discussed.
Conclusions
SBRT is a relatively effective, convenient and tolerable
retreatment option for recurrent thoracic tumors treated
prior with conventional fractionation. Overall toxicities,
while prevalent, are mostly tolerated by patients. Future
studies incorporating systemic biologic agents will need to
be conducted to evaluate efficacy and toxicity of combined
modality treatment. At the present time, SBRT is a reason-
able option for re-irradiation in previously treated lung tu-
mors. Care must be taken in the cumulative dose to nearby
critical structures and patient comorbidities, present dis-
ease burden, time from initial treatment and overall prog-
nosis should be assessed prior to proceeding with re-
irradiation.
Search strategy and selection criteria
We searched PubMed with the following keywords used in
various combinations: “lung cancer”, “carcinoma”, “local
failure”, “local recurrence”, “stereotactic body radiation
therapy (SBRT)”, “staging”, “metastasis”, “treatment”, “man-
agement”, “chemotherapy”, “radiation therapy”, “outcomes”,
“retreatment”, “survival”, and “recurrent disease”. The
search was limited to articles published in peer-reviewed
journals published from 1980 through December 2013.
Articles were also identified through searches of the au-
thors’ own files. Only papers published in English were
reviewed. The final reference list was generated on the
basis of relevance to the scope of this Review.
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